Targeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics

Abstract

Background

Cellular senescence is a fundamental characteristic of aging, marked by permanent cell cycle cessation and the release of pro-inflammatory mediators. Although senescence plays advantageous roles in tissue regeneration and tumor suppression, its accumulation leads to aging-related illnesses and functional deterioration.

Objective

This review examines the processes of cellular senescence, its effects on aging and age-related disorders, and emerging therapeutic strategies to modulate senescence for promoting healthy aging.

Methods

A thorough literature review was performed using peer-reviewed studies on cellular senescence, its molecular pathways, and therapeutic interventions. Emphasis was placed on senolytics, senomorphics, and lifestyle interventions that modulate senescence-associated pathways. Studies published in Scopus, Web of Science and PubMed between 2014–2025 were selected.

Results

Recent discoveries underscore the dual function of cellular senescence in aging and pathology. The senescence-associated secretory phenotype (SASP) fosters chronic inflammation and tissue dysfunction, connecting senescence to age-related diseases including cardiovascular conditions, dementia, and metabolic disorders. Therapeutic strategies, including senolytics (drugs that specifically eradicate senescent cells) and senomorphics (compounds that suppress SASP without killing cells), show promise in preclinical and clinical studies. Notably, dosing interals (intermittent vs continuous) influence both therapeutic efficacy and adverse events such as thrombocytopenia. Additionally, the state and limitations of clinical validation of aging biomarkers (eg, p16^INK4a, β-galactosidase) remain major hurdles for translation. Lifestyle interventions such as calorie restriction and exercise have also been identified as natural modulators of senescence pathways.

Conclusion

Targeting cellular senescence offers a promising avenue for promoting healthy aging and mitigating age-linked diseases. Continued research into senescence-modulating interventions may lead to novel therapeutics designed to prolong healthspan and lifespan.

Plain Language Summary

As we age, some of our cells stop dividing in a process called cellular senescence. These cells do not die, but instead release harmful substances that can cause inflammation and damage nearby healthy cells. While this process can be helpful early in life (like preventing cancer), too many of these cells in old age contribute to diseases such as heart problems, diabetes, and dementia.

This study reviews recent research into ways to remove or control these “senescent” cells to support healthier aging. Two promising strategies are:

• Senolytics: drugs that kill senescent cells.

• Senomorphics: drugs that make senescent cells less harmful without killing them.

Scientists are testing both types of drugs in animals and humans. Some natural compounds, like quercetin (found in apples and onions) and fisetin (found in strawberries), show potential benefits. Others like metformin and rapamycin, which are already used for diabetes or immune issues, might also help slow aging by targeting senescent cells.

The study also emphasizes that healthy habits, like exercise and calorie restriction, naturally reduce the harmful effects of senescence.

Despite promising results, challenges remain. We need more human studies to understand:

• Which treatments are safest and most effective

• How to deliver them to the right parts of the body

• How often they should be used

The authors believe that combining senolytics, senomorphics, and lifestyle changes could significantly improve our health as we age.

Graphical Abstract

Introduction

Cellular senescence is a critical biological process that contributes to aging and the onset of age-related diseases. Defined as an irreversible arrest in cell division in response to stress or damage, senescence serves as a protective mechanism to prevent the propagation of damaged cells. However, over time, the accumulation of senescent cells in tissues leads to a decline in cellular function and the development of a range of age-related conditions, including cardiovascular diseases, neurodegenerative disorders, and cancers.1,2 The presence of these cells is often accompanied by the senescence-associated secretory phenotype (SASP), a pro-inflammatory state that can exacerbate tissue dysfunction and promote chronic disease progression. As such, cellular senescence has become a focal point in aging research, offering new opportunities for therapeutic intervention.3

Recent advances in the field have introduced novel strategies aimed at targeting senescent cells to mitigate their harmful effects. Among these strategies, senolytics and senomorphics have emerged as two promising therapeutic approaches.4 Senolytics are compounds that selectively induce the death of senescent cells, thereby reducing their detrimental impact on tissues. In contrast, senomorphics work by modulating the SASP or altering the cellular environment to alleviate the negative effects of senescence without eliminating the senescent cells themselves.5 Both approaches offer a unique opportunity to delay the onset of age-related diseases and extend the healthspan, the period of life spent in good health. Despite promising preclinical findings, challenges such as specificity, safety, and clinical translation remain unresolved.6

This review aims to explore recent advancements in senolytics and senomorphics, their therapeutic potential, and the challenges in translating these strategies into clinical applications for enhancing longevity and healthspan. This study is justified as it provides a comprehensive review of recent advancements in senescence-targeting therapies, highlighting their potential, limitations, and future directions for promoting healthy aging. Unlike previous reviews that often focus on either class of therapeutics, this study integrates recent advancements, compares their mechanisms, and discusses innovative combination strategies. Additionally, it explores emerging challenges in clinical translation, including precision targeting, safety concerns, and personalized interventions, offering new perspectives on optimizing these therapies for longevity and healthspan extension. We will discuss the underlying mechanisms of cellular senescence, the progress in developing senolytics and senomorphics, and the preclinical and clinical data supporting their potential as therapeutic agents. Additionally, we will examine the challenges faced in the translation of these therapies from the laboratory to the clinic, as well as the future prospects for their application in aging-related interventions. By exploring these therapeutic avenues, this review seeks to highlight the potential of targeting cellular senescence as a strategy to promote healthy aging and reduce the burden of age-associated diseases.

This review makes a distinct contribution to the field by integrating mechanistic insights into cellular senescence with a dual therapeutic focus on both senolytics and senomorphics. While previous reviews have often addressed these approaches separately, our synthesis brings together the most recent preclinical and clinical evidence, elucidates how oxidative stress is mechanistically linked to SASP activation, and critically evaluates pharmacokinetic and bioavailability challenges that influence therapeutic translation. By consolidating evidence from 2014–2025 into comprehensive comparative tables and highlighting combination therapy strategies, we offer a novel framework for understanding how targeted senescence modulation can be optimized for healthy aging. Furthermore, the review identifies underexplored research gaps such as tissue-specific senescence heterogeneity, biomarker-driven patient selection, and advanced delivery systems, that, if addressed, could substantially advance both scientific knowledge and clinical application in geroscience.

Methodology

This narrative review was conducted through a comprehensive literature search using databases such as PubMed, Scopus, and Web of Science. Peer-reviewed articles, review papers, and clinical studies published between 2014–2025 were prioritized. Keywords including cellular senescence, aging, senolytics, senomorphics, SASP, and age-related diseases were used to identify relevant studies. Articles were selected based on their relevance to the mechanisms of senescence, its role in aging and disease, and emerging therapeutic strategies. The findings of the study were presented and discussed concurrently. Thus, this review presents current knowledge, gaps in research, and discusses potential future directions for targeting cellular senescence in healthy aging. In total, our search initially retrieved 412 records. After removal of duplicates and screening titles and abstracts for relevance, 358 articles were selected for full-text review. Following eligibility assessment based on predefined inclusion criteria, that is, relevance to cellular senescence mechanisms, therapeutic targeting (senolytics or senomorphics), and availability of clear mechanistic or clinical outcome data, 261 peer-reviewed articles were finally included in this review. Only studies published in English between 2014–2025 were considered. Inclusion criteria prioritized mechanistic studies, preclinical and clinical trials, and high-quality reviews with explicit senescence-related endpoints, while those excluded were conference abstracts, editorials, and studies lacking primary data on senescence modulation.

Cellular Senescence: Mechanisms and Implications

Cellular senescence is a complex and highly regulated process that acts as a response to various cellular stresses, including DNA damage, oxidative stress, telomere shortening, and oncogenic signaling.7 This process, which can be triggered by a variety of internal and external factors, leads to a permanent cell cycle arrest. While senescence functions as a defense mechanism against the propagation of damaged cells and thus prevent the development of cancer and other diseases, it also contributes to the aging process when senescent cells accumulate over time in tissues.8

Mechanisms of Cellular Senescence

Cellular senescence, a state of stable cell cycle arrest that prevents the proliferation of damaged or stressed cells plays a crucial role in aging, tumor suppression, and tissue remodeling. Senescence is triggered by various intrinsic and extrinsic factors, including DNA damage, telomere attrition, oncogene activation, and oxidative stress, as illustrated in Figure 1. Once senescence is established, the cell enters a state of permanent arrest and exhibits specific markers, such as β-galactosidase activity, elevated levels of p53 and p16INK4a, and changes in the chromatin landscape that reinforce its non-proliferative state.1 Understanding the molecular mechanisms underlying senescence is critical for developing interventions in aging-related diseases and cancer. The primary molecular pathways involved in senescence include:

1. DNA Damage Response (DDR) and Senescence Induction: When DNA damage occurs, the DDR pathway is activated to repair the damage. If the damage is too severe to repair, the p53-p21 pathway is triggered, inducing cell cycle arrest. This mechanism prevents the replication of damaged DNA and serves as an essential barrier against cancer.9 Additionally, the p16INK4a-Rb pathway is activated in response to cellular stress, causing another form of cell cycle arrest, particularly in older cells.10

2. Telomere Shortening: Telomeres are repetitive DNA sequences at the ends of chromosomes that protect them from damage and prevent the loss of genetic material during cell division.11 However, each cell division results in the shortening of telomeres. Once telomeres become critically short, the cell enters senescence as a protective measure to avoid chromosomal instability and potential malignant transformation.12 Telomeres shorten with each cell division due to the end-replication problem in DNA synthesis. Critically short telomeres activate the p53/p21 pathway, leading to an irreversible cell cycle arrest. The enzyme telomerase can counteract this process, but its activity is limited in most somatic cells.13

3. Oncogene-Induced Senescence (OIS): Activation of certain oncogenes, such as RAS or MYC, can induce senescence in cells, thereby preventing the transformation of these cells into tumors. OIS acts as a safeguard against the development of cancer by halting the growth of potentially malignant cells.14 In other words, oncogenic activation (eg, RAS, RAF, and MYC) can induce senescence as a protective mechanism against uncontrolled proliferation. Hyperactivation of oncogenes leads to excessive replication stress and activation of the DDR pathway.15

4. Oxidative Stress and Mitochondrial Dysfunction: Reactive oxygen species (ROS) generated from mitochondrial dysfunction or environmental stress contribute to cellular senescence.16 Oxidative stress leads to DNA damage, lipid peroxidation, and protein dysfunction.17 ROS can activate the p38 MAPK pathway, which enhances p53 and p16 signaling, reinforcing senescence.18 Importantly, oxidative stress is not an isolated mechanism but a central upstream driver of the SASP. Elevated ROS levels, whether from mitochondrial dysfunction, environmental insults, or chronic inflammation, activate redox-sensitive transcription factors such as NF-κB and p38 MAPK, which directly enhance SASP gene expression. This mechanistic link explains why oxidative stress can amplify SASP-mediated tissue damage, creating a self-reinforcing cycle of inflammation and cellular dysfunction.18 Senolytics reduce SASP not only by eliminating the senescent cells that produce high ROS but also by disrupting pro-survival signaling pathways that sustain SASP activity. For example, dasatinib and quercetin reduce SASP cytokines by promoting apoptosis of ROS-rich senescent cells, while fisetin decreases oxidative stress burden and downregulates NF-κB signaling, thereby dampening SASP output. Understanding this oxidative stress–SASP interplay highlights the need for therapeutic approaches that concurrently target mitochondrial health, redox balance, and SASP modulation.

5. Senescence-Associated Secretory Phenotype (SASP): Senescent cells develop a distinct secretory profile, known as the SASP. SASP includes pro-inflammatory cytokines (IL-6, IL-8, TNF-α), growth factors, and matrix metalloproteinases (MMPs), influencing the tissue microenvironment.19 While SASP plays roles in wound healing and tumor suppression, chronic SASP contributes to inflammation, fibrosis, and aging-related diseases.20

6. Epigenetic Regulation of Senescence: Chromatin remodeling through histone modifications and DNA methylation influences senescence. H3K9me3 and H3K27me3 histone marks promote heterochromatin formation, reinforcing senescence-associated gene silencing.21 Senescent cells also exhibit DNA methylation changes, altering gene expression patterns.22

Figure 1.

Mechanisms of Cellular Senescence (Created in BioRender. Basajja, M. (2025) https://BioRender.com/ q2r74mt).

Senescence in Aging and Age-Related Diseases

The role of cellular senescence in aging is multifaceted. While senescence may initially serve as a protective mechanism, the long-term accumulation of senescent cells in tissues can contribute to various age-related pathological conditions. Over time, senescent cells secrete a variety of pro-inflammatory factors, collectively known as the senescence-associated secretory phenotype (SASP). The SASP includes cytokines, chemokines, growth factors, and extracellular matrix-degrading enzymes, which promote local inflammation and tissue degeneration.23

1. Tissue Dysfunction: Senescent cells accumulate in various tissues as organisms age, including the skin, skeletal muscle, adipose tissue, liver, and vasculature. The presence of these cells in tissues disrupts the normal tissue architecture and impairs regenerative capacities, leading to functional decline.2 For example, in skeletal muscle, the accumulation of senescent cells has been linked to sarcopenia, the age-related loss of muscle mass and function.24

2. Chronic Diseases: The inflammatory environment created by senescent cells contributes to the pathogenesis of several chronic diseases. In the cardiovascular system, senescent cells in the blood vessels promote arterial stiffness and endothelial dysfunction, increasing the risk of hypertension and atherosclerosis.25 In the brain, the buildup of senescent cells has been implicated in neurodegenerative diseases such as Alzheimer’s and Parkinson’s, where they exacerbate neuroinflammation and neuronal loss.26 Similarly, in adipose tissue, the accumulation of senescent cells contributes to insulin resistance and the development of metabolic disorders such as type 2 diabetes.27 Senescent chondrocytes promote cartilage degradation and joint inflammation. The SASP secreted by senescent chondrocytes increases matrix metalloproteinase (MMP) activity, leading to the breakdown of cartilage and the progression of osteoarthritis.28

3. Cancer: While cellular senescence serves as a protective mechanism against tumorigenesis by halting the proliferation of damaged or oncogene-expressing cells, the chronic inflammatory environment created by senescent cells can promote cancer progression. The SASP can induce genomic instability in neighboring cells, creating a microenvironment conducive to tumor growth.29 Furthermore, the persistence of senescent cells in tissues can undermine the effectiveness of cancer therapies by altering immune surveillance and the tissue response to treatment.30

The Role of Senescence in Aging: A Double-Edged Sword

While senescence is essential for preventing the proliferation of damaged cells and the onset of cancer, its persistent presence in tissues throughout aging disrupts homeostasis. Initially protective, senescent cells transform into a detrimental factor that accelerates aging and facilitates the onset of specific chronic diseases.31 It functions as a double-edged sword, simultaneously inducing organismal deterioration and affecting health positively or negatively. Early life advantages from senescence partly by curtailing the proliferation of cancerous or damaged cells, promoting wound healing, and maintaining tissue homeostasis.32 The senescence-associated secretory phenotype (SASP) comprises bioactive substances generated by senescent cells that modify immune responses and tissue repair. Conversely, age-related senescence becomes detrimental when senescent cells accumulate due to diminished immune clearance. This results in chronic inflammation, tissue dysfunction, and age-associated diseases such as neurodegeneration, cardiovascular disorders, and cancer.3 The pro-inflammatory environment created by SASP exacerbates aging through systemic damage and diminished cellular function.33 The accumulation of senescent cells over time underscores the necessity of developing treatment strategies that selectively target these cells while preserving their beneficial roles in cancer suppression and tissue repair.34 The growing body of research on cellular senescence and its implications for aging has shifted the focus towards therapy techniques aimed at mitigating the adverse effects of senescent cells. Senolytic and senomorphic therapies have garnered significant interest as potential methods to promote healthy aging by either eliminating senescent cells or modifying their detrimental secretions.35 These medications represent a compelling domain in gerontology, aiming to restore tissue equilibrium, enhance organ functionality, and mitigate the impact of age-associated ailments.36 In greater detail, cellular senescence confers physiological benefits under specific conditions such as embryonic development, where transient senescence aids tissue patterning; wound healing, where short-term SASP signaling recruits immune cells for tissue repair; and fibrosis resolution, where senescent myofibroblasts limit excessive extracellular matrix deposition. It also serves as a robust tumor-suppressive mechanism by halting proliferation of potentially malignant cells. However, under pathological conditions such as chronic infections, metabolic dysregulation, or age-related immune decline, senescent cells persist beyond their beneficial window. This persistence is often due to reduced immune clearance efficiency, leading to prolonged SASP activity that fuels chronic inflammation, extracellular matrix degradation, and tissue dysfunction. Mechanistically, this shift from beneficial to detrimental involves sustained activation of NF-κB and p38 MAPK pathways, elevated ROS production from dysfunctional mitochondria, and unresolved DNA damage response signaling. The chronic inflammatory milieu created by these mechanisms accelerates degenerative changes in organs such as the brain, vasculature, joints, and adipose tissue. Understanding these situation-dependent roles is critical for designing interventions that selectively suppress detrimental aspects of senescence while preserving its protective functions.

Senolytics: Targeting Senescent Cells

Senolytics represent a promising class of therapeutic agents that selectively induce the death of senescent cells, thereby reducing the harmful effects these cells have on surrounding tissues. Unlike traditional approaches aimed at mitigating the consequences of aging, senolytics directly target and eliminate senescent cells, potentially reversing the negative impact of their accumulation.37 This approach offers a novel means to delay the onset of age-related diseases and improve overall healthspan. A personalised strategy integrating senolytics with traditional therapies may provide optimal benefits for healthy aging and longevity while mitigating risks.38 Table 1 below compares senolytics and traditional methods targeting cellular senescence.

Table 1.

Comparison Between Senolytics and Traditional Methods Targeting Cellular Senescence for Healthy Aging

Feature	Senolytics	Traditional Methods (Lifestyle and Natural Interventions)	References
Mechanism of Action	Selectively eliminate senescent cells	Reduce senescence accumulation via lifestyle changes	[39]
Target	Senescent cells and SASP pathway	Overall cellular health and inflammation reduction	[40]
Examples	Dasatinib, Quercetin, Fisetin, Navitoclax, Piperlongumine, Curcumin, ABT-263, UBX0101	Caloric restriction, exercise, intermittent fasting, polyphenol-rich diet (resveratrol, EGCG, luteolin), NAD+ boosters (nicotinamide riboside)	[41]
Effectiveness	Directly removes harmful senescent cells	Slows down senescence accumulation over time	[42]
Side Effects	Potential toxicity, off-target effects, immune suppression	Generally safe with minimal risks	[36]
Longevity Impact	May extend healthspan by reducing inflammation and damage	Supports longevity by promoting overall well-being	[43]
Accessibility	Requires clinical trials and prescriptions	Readily available and cost-effective	[44]
Challenges	Drug specificity, long-term safety concerns	Requires long-term adherence and lifestyle modifications	[45]
Mode of Administration	Oral or injectable drugs	Oral supplementation, functional food ingestion, physical activity, natural supplementation	[36]
Impact on Inflammation	Directly reduces pro-inflammatory SASP factors	Lowers inflammation by reducing oxidative stress and enhancing immunity	[46]
Cost	High, as many senolytics are under development or prescription-based	Low to moderate, depending on diet and supplement choices	[47]
Duration of Effect	Rapid but may require repeated dosing	Long-term benefits with sustained adherence	[35]
Interaction with Other Treatments	Potential drug interactions with chemotherapy, immunotherapy, and other medications	Generally safe and complementary to other treatments	[48]

Overview of Senolytics

Senolytics are a class of therapeutic agents specifically designed to eliminate senescent cells, which are cells that have entered an irreversible condition of cell cycle arrest while remaining metabolically active.36 Numerous stressors, such as telomere attrition, oxidative stress, DNA damage, and oncogene activation, induce cellular senescence.1 Initially, senescence safeguards against cancer by inhibiting the proliferation of damaged cells; however, the continuous accumulation of senescent cells, through the secretion of pro-inflammatory molecules known as the senescence-associated secretory phenotype (SASP), ultimately leads to chronic inflammation, tissue dysfunction, and age-related diseases.34 Senolytic therapies are designed to exploit the vulnerabilities of senescent cells, particularly their altered molecular mechanisms that heighten their susceptibility to particular stressors.37 Distinctive features include modifications in the expression of pro-survival proteins and activation of specific survival pathways. Targeting these pathways enables senolytic therapies to specifically induce programmed cell death in senescent cells while sparing non-senescent, healthy cells, hence enhancing healthspan and mitigating age-related diseases.49 In contrast to conventional anti-aging therapies that just decelerate the aging process, senolytics actively eradicate dysfunctional cells, thereby rejuvenating tissues and improving physiological function.50

Mechanisms of Action of Senolytics

Senolytics exert their effects by targeting the key survival pathways that allow senescent cells to evade apoptosis. These pathways include anti-apoptotic proteins, metabolic regulators, and inflammatory mediators, as illustrated in Figure 2 below. Different senolytic agents act through distinct molecular mechanisms, including:

1. Inhibition of Anti-Apoptotic Pathways: The BCL-2 family regulates apoptosis, and senescent cells often exhibit increased expression of anti-apoptotic (pro-survival proteins) proteins such as BCL-2, BCL-XL, and BCL-W. These proteins prevent the activation of caspases, which are essential for apoptosis. Senolytic compounds can act by inhibiting these proteins, promoting cell death in senescent cells.51,52 For instance, navitoclax (ABT-263), venetoclax, and ABT-737 are BCL-2 inhibitors that disrupt pro-survival signaling, leading to senescent cell death. These agents have shown promise in preclinical studies for reducing senescent cell burden in aging, fibrosis, and neurodegeneration.53,54

2. Disruption of the FOXO4-p53 Interaction: While p53 is a tumor suppressor protein that plays a crucial role in cellular stress responses, its prolonged activation in senescent cells contributes to cellular dysfunction.55 Senolytics can modulate the p53 pathway to promote the selective elimination of senescent cells.56 Additionally, the FOXO4 transcription factor can interact with p53 in senescent cells. This interaction blocks p53-mediated apoptosis, allowing senescent cells to survive.57 FOXO4-DRI, a synthetic peptide, disrupts the FOXO4-p53 interaction, reactivating apoptosis and clearing senescent cells. This approach has demonstrated effectiveness in reversing age-related decline in animal models.58

3. Suppression of Senescence-Associated Secretory Phenotype (SASP): Senescent cells secrete pro-inflammatory cytokines (IL-6, IL-8, TNF-α), growth factors, chemokines, and matrix metalloproteinases, which create a pro-inflammatory environment that accelerates aging and disease progression.59 For example, dasatinib and quercetin is a combination therapy that reduces SASP production and enhances the clearance of senescent cells.60 Similarly, fisetin and curcumin are flavonoids with senolytic properties that inhibits SASP secretion, reduce inflammation and improve tissue function.61,62

4. Targeting Heat Shock Proteins (HSPs): Heat shock proteins (HSP90, HSP70) are molecular chaperones that stabilize key proteins involved in senescence.63 HSP90 inhibitors (eg, 17-AAG, Geldanamycin) cause degradation of senescence-associated proteins, leading to senescent cell death. This approach is being explored in fibrosis, neurodegenerative diseases, and cancer therapy.64,65

5. Modulation of Metabolic Pathways: Senescent cells exhibit altered metabolism, particularly increased reliance on glycolysis and mitochondrial dysfunction. When senescent cells exhibit mitochondrial dysfunction, it leads to an altered cellular redox state. This provides an opportunity for senolytic agents to exploit the altered metabolism of these cells, inducing oxidative stress and cell death.66 For instance, metformin reduces mitochondrial oxidative stress and modulates AMPK signaling, helping prevent the accumulation of senescent cells.67,68 Resveratrol on the other hand activates SIRT1 and AMPK, which promote mitochondrial health and energy balance while NAD⁺ boosters (such as nicotinamide riboside, nicotinamide mononucleotide) improve mitochondrial function, counteract cellular senescence, and extend lifespan in animal models.69

6. Enhancement of Autophagy and Cellular Clearance: Autophagy is a process that removes damaged organelles and proteins, but senescent cells often exhibit impaired autophagy, leading to metabolic dysfunction. This can serve as a therapeutic target against aging and age-related disorders.70 For example, rapamycin, an mTOR inhibitor restores autophagy and delays senescence-related diseases.71,72 Similarly, spermidine induces autophagy and improves cellular renewal, thus promoting longevity.73

7. Regulation of Oxidative Stress and DNA Damage Response: Oxidative stress and DNA damage are major drivers of senescence. Some senolytics mitigate these effects by enhancing antioxidant defenses. A common example is sulforaphane, found in cruciferous vegetables, which activates Nrf2, a master regulator of antioxidant pathways.74 Similarly, coenzyme Q10 supports mitochondrial health and reduces oxidative stress-related senescence.75

Figure 2.

Mechanisms of Action of Senolytics (Created in BioRender. Basajja, M. (2025) https://BioRender.com/ td8igwu).

Key Senolytic Compounds and Their Mechanisms of Action

A variety of compounds have been identified as potential senolytics, each with distinct mechanisms of action. These compounds have shown promise in preclinical models and are currently undergoing evaluation in clinical trials to assess safety, effectiveness, and long-term benefits (Table 2).

Table 2.

Key Senolytic Compounds, Their Mode of Action, and Evidence from Preclinical and Clinical Trials

Senolytic Compound	Mode of Action	Evidence from Preclinical Trials	Evidence from Clinical Trials
Navitoclax (ABT-263)	Inhibits BCL-2, BCL-xL, and BCL-W, leading to apoptosis of senescent cells.	- Reduces senescent cell burden in mice models of aging and fibrosis. - Improves lung function in idiopathic pulmonary fibrosis (IPF).76 -The elimination of senescent cells by navitoclax (ABT263) suppresses osteoclastogenesis in mice77 -The removal of senescent cells by ABT263 revitalises aged haematopoietic stem cells in mice78	- Limited large-scale trials yet. Concerns over thrombocytopenia due to BCL-xL inhibition.79 Some clinical trials: NCT04472598, NCT03222609, NCT04468984, NCT0597621739
Dasatinib + Quercetin (D+Q)	- Dasatinib inhibits tyrosine kinases, blocking senescent cell survival. - Quercetin inhibits PI3K/AKT and SASP secretion.	- Eliminates senescent cells and reduces bone loss in aging mice80 -Enhanced vasomotor function in aged and atherosclerotic mice 81 - Improves physical function and lifespan in aged mice.82	- Shown to reduce senescent cell burden and improved functional capacity in patients with idiopathic pulmonary fibrosis patients (phase 1B 2019) -Chronic myelogenous leukemia and Acute Lymphoid Leukemia (FDA approved 2006)83
FOXO4-DRI	Disrupts FOXO4-p53 interaction, reactivating apoptosis in senescent cells.	- Rejuvenates tissues and stem cells in aged mice.84 -Alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice85 -Improves spermatogenesis in aged mice86	- Limited completed clinical trials: NCT03513016, NCT04349956, NCT04229225.39
Fisetin	Modulates SASP secretion, activates AMPK/SIRT1, promotes apoptosis.	- Increases lifespan in mice.87 - Fisetin mitigates oxidative stress, inflammation, and apoptosis in diabetic cardiomyopathy in rats.88	- Clinical trials: NCT05758246, NCT05505747, NCT04815902, NCT0421098639 - Shown to reduce markers of senescence in human adipose tissue.87
Venetoclax	Selectively inhibits BCL-2, inducing senescent cell death.	-Effective in reducing acute myeloid leukemia cells.89 - Potential use against cancer therapy-induced senescent growth and metabolic disorders.90	- FDA-approved for chronic lymphocytic leukemia (CLL) but not yet for aging-related conditions.91 Venetoclax improves clinical outcomes in newly diagnosed acute myeloid leukemia patients92,93
ABT-737	Mimics BH3-only proteins to inhibit BCL-2, promoting apoptosis.	- Eliminates senescent cells in fibrotic and aged tissues in mice.94	- No clinical trials yet due to potential off-target effects.
17-AAG (Tanespimycin)	Inhibits HSP90, destabilizing proteins essential for senescent cell survival.	- Suppresses senescent fibroblasts in models of fibrosis and cancer.95	- Investigated in cancer therapy trials, but no anti-aging trials yet 96
Curcumin	Modulates NF-κB and p53, enhances autophagy, prevents SASP accumulation.	- Reduces senescence-related inflammation and oxidative stress in rats.97	- Clinical studies for anti-inflammatory, neuroprotective and improved cognitive effects98,99
Resveratrol	Activates SIRT1, reduces oxidative stress, improves mitochondrial function.	- Extends lifespan in animal models like flies, silkworms, fish.100,101 - Improves vascular function and metabolism in mice and rats.102	- Some trials show benefits for cardiovascular and metabolic health, but limited senolytic-specific trials.103–105
Metformin	Activates AMPK, reduces mTOR signaling, prevents senescence accumulation.	- Increases lifespan in rodents.106 - Reduces inflammation and improves aging outcome in obese rats.107	- The TAME trial (Targeting Aging with Metformin) is ongoing to assess its role in healthy aging.
Rapamycin	Inhibits mTOR, enhances autophagy, delays cellular aging.	- Extends lifespan in mice and improves immune function.108	- Being tested in human clinical trials for aging and immune function enhancement and the outcomes have been promising72
Sulforaphane	Activates Nrf2, enhances antioxidant defenses, reduces SASP.	Protects against inflammation and oxidative stress in aging-related disorders like osteoarthritis in mouse and rat models.109,110	Investigated for cancer prevention and anti-inflammatory benefits.111
Piperlongumine	Induces reactive oxygen species (ROS) production, selectively killing senescent cells.	Promotes apoptosis of osteosarcoma cells and thus inhibited osteosarcoma progression in vitro112 -Induces cell cycle arrest and apoptosis in vitro and in vivo via the ROS/Akt pathway in human thyroid cancer cells113	Being explored for potential anti-cancer and anti-aging applications.
Bardoxolone Methyl	Modulates Nrf2 signaling, reducing oxidative damage in senescent cells.	Improves renal function and mitochondrial efficiency in aging mouse models.114,115	Tested in clinical trials for kidney disease, but its senolytic effects remain under investigation.116
UBX0101	Blocks Mdm2-p53 interaction, promoting senescent cell clearance.	Eliminates senescent chondrocytes, preventing osteoarthritis progression in mice.117	Phase 1 clinical trials showed some benefits for osteoarthritis, but Phase 2 did not record any benefit, thus, further studies are needed118

Challenges in Senolytic Therapy

Despite the promising potential of senolytic therapy in combating aging and age-related diseases, several challenges must be addressed before widespread clinical application. These challenges include safety concerns, drug specificity, delivery methods, off-target effects, long-term consequences, and regulatory hurdles. Addressing these issues through better drug design, personalized treatment approaches, and rigorous clinical research will be crucial for making senolytics a viable therapeutic option in the future.

1. Safety and Toxicity Concerns: Many senolytic drugs, such as navitoclax (ABT-263), target BCL-2 family proteins, which are also essential for the survival of non-senescent cells, including platelets and immune cells. This can lead to severe side effects, including thrombocytopenia (low platelet count) and immune suppression, increasing the risk of infections.36 Long-term use of senolytics could potentially cause tissue damage, impaired wound healing, or unintended apoptosis in healthy cells.119

2. Lack of Senescent Cell-Specific Targets: One of the major challenges in senolytic therapy is ensuring the selective elimination of senescent cells without affecting healthy cells. While certain senolytic compounds have shown specificity for senescent cells in preclinical models, achieving this selectivity in humans remains a significant hurdle.120 For example, some senescence-associated proteins (eg, BCL-2, p53, SASP factors) are also expressed in normal, proliferating cells, leading to potential off-target effects.31 Therefore, optimizing senolytic agents to minimize side effects while maintaining efficacy is crucial.

3. Drug Delivery Challenges: Senolytic drugs need to penetrate different tissues efficiently, but bioavailability and tissue specificity remain major hurdles. Some senolytics, such as FOXO4-DRI, require peptide-based delivery, which is complex and may limit clinical application.58 Blood-brain barrier penetration is another challenge, making it difficult for senolytics to target neurodegenerative diseases effectively.121

4. Long-Term Consequences and Need for Repeated Treatment: The long-term effects of senolytic therapy remain unclear, as eliminating senescent cells could disrupt tissue homeostasis. Senescent cells accumulate over time, meaning that senolytic treatment may need to be repeated periodically, raising concerns about chronic drug administration and potential cumulative side effects.122

5. Variability in Response and Individual Differences: Senescence is influenced by genetic factors, lifestyle, and environmental exposures, meaning that not all individuals may respond equally to senolytic therapy.123 Age-related changes in metabolism and drug clearance could also impact the effectiveness and safety of senolytics in older adults.124

6. Dosing and Treatment Scheduling: Determining the ideal dose and treatment schedule for senolytic therapies is complex. Since the burden of senescent cells increases with age, repeated or long-term treatment may be necessary to maintain therapeutic benefits. However, frequent dosing of senolytics may increase the risk of adverse effects, making it essential to find the right balance between efficacy and safety.36 Emerging clinical and preclinical evidence suggests that intermittent senolytic dosing may reduce the risk of cumulative toxicity, including thrombocytopenia observed with agents such as navitoclax, while preserving efficacy.36 Continuous dosing, while potentially providing sustained clearance, increases exposure-related risks. Thus, optimizing interval schedules, potentially through biomarker-guided timing remains a critical translational challenge.

7. Ethical and Regulatory Challenges: Regulatory approval for senolytic drugs is challenging because aging is not officially classified as a disease by the Food and Drug Agency (FDA) or European Medicine Agency EMA, making it harder to obtain approval for anti-aging treatments.125 Ethical concerns regarding the use of senolytics for life extension and enhancement rather than disease treatment could create societal and policy debates. High costs of development and intellectual property issues may limit access to senolytic therapies for wider populations.126

8. Need for More Clinical Trials: While preclinical data are promising, large-scale, long-term clinical trials are needed to evaluate efficacy, safety, and optimal dosing of senolytics in humans. Ongoing trials (eg, TAME trial for Metformin, D+Q trials for aging-related diseases) will provide critical insights, but more diverse human studies are required.127

9. Bioavailability Challenge: In terms of translational application, bioavailability remains a significant challenge for many senolytic compounds, particularly plant-derived polyphenols such as fisetin and quercetin, which exhibit poor oral absorption, rapid metabolism, and low systemic retention. Preclinical studies often administer fisetin at doses ranging from 20–100 mg/kg orally (PO) in mice, while dasatinib is typically dosed at 5–10 mg/kg PO. In early human trials, the Dasatinib plus Quercetin (D+Q) regimen has used 100 mg/day dasatinib combined with 1000 mg/day quercetin for 3 consecutive days per month, showing acceptable tolerability but variable pharmacokinetic profiles. These limitations underscore the need for delivery innovations such as nanoparticle encapsulation, liposomal formulations, and prodrug designs to enhance bioavailability, protect compounds from first-pass metabolism, and improve tissue-specific targeting. Moreover, pharmacokinetic studies should characterize parameters such as maximum plasma concentration (Cmax), half-life (t½), and area under the curve (AUC) to guide optimal dosing regimens. Integrating such data into clinical translation will facilitate the rational design of dosing schedules that balance efficacy with safety. Nanotechnology and advanced drug delivery systems can enhance the bioavailability, stability, and targeted delivery of senomorphic compounds by encapsulating them in nanoparticles or liposomal carriers.

Senomorphics: Modulating the Senescence-Associated Secretory Phenotype (SASP)

Unlike senolytic therapies that aim to directly eliminate senescent cells, senomorphics work by modulating the senescence-associated secretory phenotype (SASP), which consists of pro-inflammatory cytokines, chemokines, growth factors, and extracellular matrix-degrading enzymes secreted by senescent cells. By targeting the SASP, senomorphic therapies aim to alleviate the detrimental effects of senescence without necessarily removing the senescent cells.128 This approach provides a novel strategy to mitigate the harmful inflammation, tissue degradation, and chronic diseases associated with cellular senescence, while preserving the beneficial aspects of senescence, such as tumor suppression and tissue repair.129

Overview of Senomorphics

Senomorphic agents target the SASP or the molecular pathways that drive it. These compounds aim to reduce inflammation, restore tissue homeostasis, and promote tissue regeneration by modulating the environment surrounding senescent cells.130 Unlike senolytics, which focus on cell death, senomorphics maintain the senescent cell’s presence but modify its behavior, particularly the pro-inflammatory and tissue-damaging components of the SASP.129 By reducing the detrimental effects of senescent cells, such as the SASP, senomorphics hold promise for treating a range of diseases, including cancer, neurodegenerative disorders, cardiovascular diseases, and metabolic syndromes.26

At the molecular level, senomorphics exert their effects primarily by modulating the signaling pathways that govern SASP production without inducing apoptosis in senescent cells. This often involves inhibition of pro-inflammatory transcription factors such as NF-κB and C/EBPβ, suppression of p38 MAPK and mTOR signaling, and enhancement of autophagic flux to reduce the accumulation of damaged organelles and protein aggregates. For instance, rapamycin attenuates SASP by inhibiting mTORC1-dependent translation of IL-1α, a key upstream SASP regulator, while metformin activates AMPK to indirectly suppress NF-κB activity and lower pro-inflammatory cytokine secretion. Flavonoids like apigenin and luteolin downregulate MAPK and JAK/STAT pathways, leading to broad SASP suppression. By altering the secretory profile of senescent cells, senomorphics can mitigate tissue inflammation and promote a microenvironment more conducive to regeneration, while preserving the beneficial growth-arrest functions of senescence. This mechanistic distinction from senolytics is crucial for situations where complete removal of senescent cells may be undesirable, such as in wound healing or tissue repair.

Mechanisms of Actions of Senomorphics

Senomorphics target various molecular pathways involved in cellular senescence, effectively modulating the detrimental aspects of the senescent phenotype while preserving beneficial aspects. Simply put, senomorphics work by modulating key pathways that regulate the SASP. Some of the key mechanisms include the following and illustrated in Figure 3.

1. NF-κB Pathway: The nuclear factor-kappa B (NF-κB) pathway plays a central role in regulating the expression of pro-inflammatory cytokines and other SASP factors. In senescent cells, NF-κB is often constitutively activated, driving chronic inflammation.131 Senomorphic agents can inhibit this pathway, reducing the secretion of inflammatory cytokines and alleviating the deleterious effects of chronic inflammation.132

2. JAK/STAT Pathway: The Janus kinase (JAK) signal transducer and activator of transcription (STAT) pathway is involved in the inflammatory signaling of senescent cells. Inhibition of the JAK/STAT pathway can reduce the secretion of pro-inflammatory cytokines and mitigate the impact of senescence-induced inflammation.133

3. mTOR Pathway: The mechanistic target of rapamycin (mTOR) pathway is implicated in aging and senescence. Activation of mTOR in senescent cells contributes to cellular dysfunction and the pro-inflammatory SASP.134 Inhibition of mTOR has been shown to reduce the expression of SASP factors and improve tissue function in animal models of aging.135

4. Modulation of the SASP: Senescent cells secrete a variety of pro-inflammatory cytokines, chemokines, growth factors, and proteases collectively known as the SASP. This secretory profile contributes to chronic inflammation, which is a hallmark of aging and a driver of multiple diseases. Senomorphics reduce SASP activity, thereby lowering inflammation, preventing tissue damage, and mitigating age-related diseases.3

5. Epigenetic and Transcriptomic Regulation: Cellular senescence is associated with widespread epigenetic changes, including alterations in DNA methylation, histone modifications, and chromatin remodeling. Senomorphics target these epigenetic regulators to reverse or slow down senescence.136 Some compounds reactivate silenced genes or suppress harmful gene expression, thus modifying the aging process at the molecular level.137

6. Maintenance of Mitochondrial and Metabolic Homeostasis: Mitochondrial dysfunction is a major driver of cellular senescence, leading to increased reactive oxygen species (ROS) production, metabolic decline, and energy deficits.138 Senomorphics enhance mitochondrial function by stimulating mitophagy (removal of damaged mitochondria), improving oxidative phosphorylation, and reducing oxidative stress, thereby promoting healthier cellular metabolism.66

7. Modulation of DNA Damage Response (DDR) and p53/p21 Pathways: Cellular senescence is often triggered by DNA damage, which activates the DNA damage response (DDR) and key regulatory pathways such as p53/p21 and p16INK4a/Rb.55 While these pathways prevent damaged cells from proliferating, they also promote inflammation and tissue dysfunction if senescent cells persist. Senomorphics modulate these pathways to restore cell cycle control and improve tissue regeneration while maintaining the tumor-suppressive benefits of senescence.139

Figure 3.

Mechanisms of Action of Senomorphics (Created in BioRender. Basajja, M. (2025) https://BioRender.com/ z3l9g0q).

Differences Between Senolytics and Senomorphics

The major difference between senolytics and senomorphics lies in their mechanism of action on senescent cells. Senolytics selectively eliminate senescent cells by inducing apoptosis, thereby reducing their harmful effects on aging and disease. Senomorphics modulate the behavior of senescent cells, suppressing their harmful secretions (SASP) without killing them, aiming to restore function and reduce inflammation.36,37 In short, senolytics kill senescent cells, while senomorphics reprogram them to be less harmful. A combination of both strategies may provide a more balanced approach to mitigating aging-related pathologies while preserving essential cellular functions.140 Table 3 highlights some major differences between senolytics and senomorphics.

Table 3.

Some Major Differences Between Senolytics and Senomorphics

Feature	Senolytics	Senomorphics	References
Definition	Compounds that selectively induce apoptosis in senescent cells, leading to their elimination.	Compounds that modulate the phenotype of senescent cells without killing them, primarily by suppressing harmful secretions.	[36,37]
Mechanism of Action	Induce apoptosis in senescent cells, leading to their elimination.	Modulate senescent cell behavior without killing them, primarily by suppressing SASP.	[49,65]
Therapeutic Goal	Remove senescent cells to reduce their harmful effects on aging and disease.	Preserve senescent cells while minimizing their pro-inflammatory and deleterious effects.	[50,119]
Target Cells	Specifically targets and eliminates senescent cells.	Alters the function of senescent cells without clearing them.	[141]
Key Molecular Targets	BCL-2 family proteins, PI3K/AKT, FOXO, p53 pathways (apoptosis regulators).	NF-κB, mTOR, SIRT1, p53/p21 pathways (inflammatory and metabolic regulators).	[31,142]]
Effect on SASP	Eliminates SASP-producing cells, thereby reducing systemic inflammation.	Suppresses SASP production while maintaining beneficial senescence functions.	[143]
Examples of Agents	Dasatinib, Quercetin, Fisetin, Navitoclax (ABT-263).	Metformin, Rapamycin, Resveratrol, Curcumin.	[130,141]
Potential Benefits	Clears damaged cells, improving tissue function and lifespan.	Reduces chronic inflammation, enhances tissue repair, and improves metabolic function.	[36,65]
Associated Risks	Risk of excessive cell depletion, potential toxicity, and off-target effects.	May require long-term use, as it does not eliminate senescent cells completely.	[4,119]
Therapeutic Applications	Used in conditions where removing senescent cells is beneficial, such as osteoarthritis, fibrosis, and neurodegeneration.	Suitable for diseases where senescent cell modification is preferred, such as metabolic disorders and neuroprotection.	[144]
Mode of Administration	Typically administered intermittently to avoid excessive depletion of senescent cells.	Requires continuous or long-term administration to sustain SASP suppression.	[40]

Key Senomorphic Compounds and Their Mechanisms of Action

Several compounds have been identified as potential senomorphics, each targeting different components of the SASP or senescence-associated signaling pathways. These agents aim to modify the senescent cell’s secretory phenotype, suppress inflammation, and promote tissue homeostasis. While animal models have shown encouraging results, the translation of these therapies to humans remains in early stages. Table 4 highlights some senomorphic compounds, their mode of action, and evidence from preclinical and clinical trials.

Table 4.

Key Senomorphic Compounds, Their Mode of Action, and Evidence from Preclinical and Clinical Trials

Senomorphic Compound	Mode of Action	Preclinical Evidence	Clinical Evidence
Metformin	Activates AMPK, inhibits mTOR, suppresses NF-κB signaling, and reduces SASP secretion.145	Reduces inflammation, improves lifespan, enhances metabolic function in animal models.106	The TAME trial is evaluating its anti-aging effects; shown to improve metabolic health and reduce age-related diseases.146
Rapamycin	Inhibits mTOR signaling, reduces SASP, enhances autophagy, and improves mitochondrial function.147	Extends lifespan in mice, improves immune function, reduces age-related diseases.108	The PEARL study suggests benefits in immune aging; potential applications in age-related diseases.148
Resveratrol	Activates SIRT1, reduces oxidative stress, and suppresses inflammatory SASP factors.149	Improves cardiovascular and metabolic health, reduces inflammation in animal models.150	Clinical trials suggest anti-aging and anti-inflammatory effects, but bioavailability is a challenge.151
Curcumin	Inhibits NF-κB and JAK/STAT pathways, reduces SASP secretion, and modulates epigenetic aging markers.152	Reduces inflammation, protects against neurodegeneration, and improves metabolic function in animal models.153	Clinical trials show potential in reducing cognitive decline and improving metabolic disorders.154
Epigallocatechin Gallate (EGCG)	Suppresses SASP via inhibition of NF-κB, reduces oxidative stress, and enhances autophagy.155	Demonstrates anti-inflammatory and neuroprotective effects in animal models.156	Clinical trials suggest benefits in metabolic health, neuroprotection, and cardiovascular health.157,158
Quercetin	Inhibits NF-κB, reduces SASP, and modulates PI3K/AKT signaling.159	Reduces senescence markers and inflammation, extends lifespan in preclinical studies.60,160	Combined with Dasatinib in clinical trials for reducing senescent cell burden.161
Fisetin	Suppresses SASP by inhibiting mTOR and NF-κB, enhances SIRT1 activity.162	Extends lifespan, reduces senescence markers, arterial dysfunction, and protects against inflammation in animal studies.163,164	Ongoing clinical trials assessing its role in promoting healthy aging and reducing inflammation in humans are promising.61
Apigenin	Inhibits JAK/STAT and NF-κB, reduces inflammatory SASP factors.165	Shows protective effects in neurodegeneration and cardiovascular health in animal studies.166	Limited clinical evidence, but early trials suggest potential benefits in inflammation and aging-related diseases.167
Pterostilbene	Activates SIRT1, reduces oxidative stress, and modulates SASP.168	Demonstrates anti-inflammatory and cognitive benefits in animal models.169	Early clinical trials indicate potential benefits for longevity and cognitive function.170
Nicotinamide Riboside (NR)	Boosts NAD+ levels, activates SIRT1, and reduces SASP production.171	Enhances mitochondrial function, reduces senescence, and improves metabolic health in preclinical models.172	Clinical trials suggest benefits in metabolic and neurodegenerative diseases, showing improved NAD+ levels in aging individuals.173
Spermidine	Enhances autophagy, modulates mitochondrial function, and reduces SASP.174	Extends lifespan in multiple animal models, improves cognitive function, and reduces inflammation.175	Clinical trials suggest cognitive benefits but elavatad plasma level detrimental to brain aging.176,177
α-Ketoglutarate (AKG)	Supports mitochondrial function, reduces inflammation, and modulates epigenetic aging markers.178	Improves lifespan and metabolic health in preclinical mice models.179	Early clinical trials show potential in reducing biological age and improving overall healthspan.180
Berberine	Activates AMPK, reduces oxidative stress, and modulates inflammatory SASP factors.181	Improves metabolic health, reduces cellular senescence, and enhances autophagy in preclinical models.182	Clinical trials show benefits in glucose metabolism, cardiovascular health, and inflammation control.183
Sulforaphane	Activates Nrf2, suppresses SASP, reduces oxidative stress, and enhances detoxification pathways.184	Protects against neurodegeneration, cardiovascular diseases, and inflammation in animal studies.185	Clinical trials indicate benefits in cognitive function, metabolic health, and detoxification.186
Ginsenosides	Modulate inflammatory pathways, enhance autophagy, and reduce senescence markers.187	Improve metabolic and immune function, reduce cellular senescence in preclinical models.188,189	Clinical trials suggest benefits in cognitive health, immune modulation, and longevity.190

Challenges and Opportunities in Senomorphic Therapy

Senomorphic therapy offers a promising approach to mitigating the harmful effects of cellular senescence without eliminating the beneficial functions of senescent cells and thus holds great promise in combating age-related diseases. However, there are several challenges to overcome in its development and application. At the same time, there are significant opportunities that could accelerate progress and widen its therapeutic scope.

Challenges in Senomorphic Therapy

1. Limited Clinical Evidence: While preclinical studies in animal models suggest that senomorphic compounds can effectively modulate the effects of senescence, clinical trials in humans are still relatively limited. Large-scale randomized controlled trials (RCTs) are needed to confirm the long-term safety and efficacy of these compounds, particularly in preventing or mitigating age-related diseases like Alzheimer’s disease, osteoarthritis, and cardiovascular disorders.123 Most current evidence comes from short-term studies or observational data, which makes it difficult to determine the real-world, long-term effects.191

2. Translating Preclinical Findings to Humans: While animal models have shown encouraging results, the translation of these therapies to humans remains challenging.192 Species differences, variations in the aging process, and the complexity of human aging may complicate the successful application of senomorphic agents in clinical practice.193 Therefore, further clinical trials are needed to validate the efficacy and safety of these agents in human populations.

3. Variability in Senescence Markers: Senescence is a complex biological process with different markers and hallmarks depending on tissue type, age, and the specific stressors that triggered senescence. Identifying consistent and reliable biomarkers to measure senescence in humans remains a significant hurdle. Moreover, SASP factors vary across tissues, making it difficult to design universal interventions. This variability complicates the development of a standardized approach for measuring therapeutic outcomes and assessing the effectiveness of senomorphic treatments.194

4. Bioavailability and Pharmacokinetics: Many senomorphic compounds, such as curcumin and resveratrol, have poor bioavailability when administered orally, meaning they are not efficiently absorbed or utilized in the body.195 This is a critical challenge because without proper absorption, these compounds cannot exert their beneficial effects on senescence. Researchers are exploring various drug delivery strategies, such as liposomal formulations, nanoencapsulation, and prodrug strategies, to improve the bioavailability and targeted delivery of senomorphic compounds to specific tissues affected by senescence.196

5. Potential Off-Target Effects: While senomorphic compounds are designed to modulate the senescence process without clearing senescent cells completely, there is a risk of unwanted off-target effects.197 Senescence plays a protective role in certain contexts, such as tumor suppression and wound healing. Chronic suppression of senescence or the SASP could potentially interfere with these beneficial processes. For instance, inhibiting SASP may reduce inflammation but could also impair the immune system’s ability to fight infections or prevent cancerous growths.194 Similarly, inhibition of mTOR can impair immune function, and restoring NAD⁺ levels could potentially affect metabolic processes.198 As such, careful monitoring of patients undergoing senomorphic therapy is necessary to prevent adverse effects.

6. Heterogeneity of Senescent Cells: Senescent cells are heterogeneous, meaning that not all senescent cells behave the same way in different tissues and organs. For example, senescence in muscle cells might cause dysfunction through a different mechanism compared to senescence in endothelial cells. This diversity complicates the development of broad-spectrum senomorphic therapies.31 Senomorphic compounds that work effectively in one tissue might not produce the same results in others, requiring tailored or tissue-specific therapies.199

7. Regulatory Hurdles: Senomorphic therapies, particularly those derived from natural compounds (eg, resveratrol, curcumin), may face challenges in regulatory approval. These compounds are often classified as nutraceuticals or dietary supplements, which are not subject to the same rigorous testing and regulatory requirements as pharmaceutical drugs.200 However, for senomorphic therapies to be used as effective interventions, they will likely need to undergo extensive clinical testing and receive approval from health authorities like the FDA or EMA.126 Regulatory frameworks may need to be adapted to accommodate new therapeutic paradigms based on modulating senescence.

8. Drug Synergy and Combinatorial Approaches: Combining senomorphic compounds with other therapeutic strategies, such as senolytics (which eliminate senescent cells), caloric restriction mimetics, or antioxidants, could potentially enhance therapeutic outcomes. However, the interactions between these treatments are not fully understood. There is a need for more systematic studies to determine how senomorphics and senolytics can be used in combination to optimize the treatment of aging and age-related diseases. Additionally, the long-term safety of combinatorial treatments remains unclear.36

Opportunities in Senomorphic Therapy

1. Targeting Age-Related Diseases: Senomorphic therapy offers tremendous potential in treating a wide range of chronic age-related diseases. By modulating the harmful effects of senescence, these therapies could slow down or even reverse conditions such as neurodegenerative diseases (eg, Alzheimer’s, Parkinson’s), cardiovascular disease, arthritis, and metabolic disorders (eg, type 2 diabetes).193 Since many of these diseases are associated with the accumulation of senescent cells and their inflammatory secretions, senomorphic compounds have the potential to treat the root cause of these diseases, rather than just alleviating symptoms.201

2. Personalized Medicine Approaches: As our understanding of individual aging profiles and senescence mechanisms deepens, there is an opportunity to design personalized treatments based on a person’s genetic makeup, lifestyle factors, and specific senescence-related conditions. Biomarker-based diagnostics will allow for more precise identification of individuals who would benefit most from senomorphic therapy.202 Personalized medicine has proven to help in disease diagnosis, minimize side effects and maximize the therapeutic approaches.203

3. Combination with Senolytics: Senomorphic therapy could be used in combination with senolytic compounds (which selectively kill senescent cells). While senolytics eliminate the senescent cells that accumulate over time, senomorphics can help modulate the negative effects of the remaining senescent cells. The combination of these therapies could provide a synergistic effect, improving tissue function, reducing inflammation, and slowing down aging processes. This approach could enhance the overall effectiveness of treatments for age-related diseases.65

4. Advancements in Drug Delivery Systems: Nanotechnology and advanced drug delivery systems offer the potential to improve the bioavailability, stability, and targeted delivery of senomorphic compounds. By encapsulating these compounds in nanoparticles or using liposomal carriers, researchers can enhance the efficiency of drug delivery to specific tissues or organs. These delivery technologies may allow for more precise treatment of senescence in key tissues (such as the brain, heart, or joints), thereby improving therapeutic outcomes.204

5. Expansion into Preventive Medicine: Instead of focusing solely on treating diseases, senomorphic therapies could be used for preventive purposes. Early intervention with senomorphic compounds could delay the onset of age-related diseases by modulating senescence in at-risk individuals, potentially leading to an extension of healthspan (the period of life spent in good health).35,130 This preventive approach could be especially beneficial for populations with genetic predispositions to certain conditions or those already showing early signs of aging-related decline.

6. Potential for Nutraceutical Development: Many senomorphic compounds are naturally occurring and are already consumed as part of a healthy diet (eg, resveratrol, curcumin, quercetin). These compounds could be developed as dietary supplements or functional foods that support healthy aging and reduce the risk of age-related diseases. Their natural origin may make them appealing to consumers seeking less invasive, more holistic health solutions.130,205 As research progresses, these compounds could be integrated into preventive health regimens.

7. Integration with AI and Systems Biology: The application of artificial intelligence (AI) and systems biology approaches in drug discovery can help accelerate the identification of new senomorphic compounds. AI-driven analyses can uncover novel compounds and predict their senescence-modulating properties based on biological data.206 Moreover, systems biology approaches that analyze the complex networks of cellular aging processes could help uncover new targets for senomorphic therapies and optimize their clinical applications.207

Combination Therapies: Synergizing Senolytics and Senomorphics

While both senolytics and senomorphics offer promising approaches for targeting cellular senescence, recent research suggests that combining these two therapeutic strategies may enhance their individual benefits, leading to more robust outcomes in promoting healthy aging. By simultaneously eliminating senescent cells and modulating the harmful effects of their secretory phenotype, combination therapies hold the potential to address the multifaceted nature of aging and age-related diseases.39,119 This integrated approach offers a comprehensive strategy for improving healthspan, reducing chronic inflammation, and enhancing tissue regeneration.

Rationale for Combination Therapies

The rationale for combining senolytic and senomorphic therapies lies in the complementary mechanisms of action of these two approaches. Senolytic agents focus on clearing the burden of senescent cells, directly addressing the source of cellular dysfunction, while senomorphics target the pro-inflammatory and tissue-degrading effects of the SASP, which result from the senescence process. When used in combination, these therapies can not only reduce the number of senescent cells but also ameliorate the systemic inflammation and tissue damage that occurs as a result of senescence. This dual approach has the potential to enhance the overall therapeutic effect, improving the health of tissues, organs, and systems affected by aging.208,209 Furthermore, cellular senescence is a complex process that cannot be fully addressed by targeting a single aspect, such as cell clearance or SASP modulation. Senolytic therapies may eliminate senescent cells but may not fully resolve the long-term inflammatory consequences of their presence, while senomorphic agents may suppress the SASP but leave senescent cells intact, allowing them to persist and potentially cause harm.210 Combining both approaches addresses the complexity of senescence, offering a more holistic therapeutic strategy for aging-related conditions.45

Potential Applications of Combination Therapies

The combination of senolytic and senomorphic therapies has broad potential applications in age-related diseases and conditions. Some key areas where combination therapies may offer substantial benefits include:

1. Cardiovascular Disease: Cellular senescence plays a key role in the development of cardiovascular diseases, particularly through the accumulation of senescent cells in blood vessels and the heart. By using senolytics to remove senescent endothelial and smooth muscle cells, combined with senomorphics like rapamycin to modulate the SASP, this dual approach could reduce arterial stiffness, improve vascular function, and lower the risk of heart attacks and stroke.211,212

2. Neurodegenerative Diseases: Conditions like Alzheimer’s disease, Parkinson’s disease, and other forms of dementia are characterized by neuroinflammation and the accumulation of senescent cells in the brain.26 Combination therapies targeting both senescent cells and the neuroinflammatory SASP could slow disease progression, improve cognitive function, and promote neuronal repair.213 Senolytics like dasatinib and quercetin, combined with senomorphic agents such as NMN, could help rejuvenate neuronal tissue and prevent cognitive decline.214

3. Osteoporosis and Sarcopenia: Aging is associated with a decline in bone density and muscle mass, partly driven by the accumulation of senescent cells in bone and muscle tissue. The combination of senolytics and senomorphics could rejuvenate both bone and muscle tissue by eliminating senescent cells and modulating the inflammatory environment that promotes bone resorption and muscle wasting.215 Such therapies could reduce the risk of fractures, improve muscle strength, and enhance mobility in the elderly.216

4. Cancer: Cellular senescence is a double-edged sword in cancer. While senescence acts as a protective mechanism against tumorigenesis, the accumulation of senescent cells and their inflammatory SASP can promote tumor progression.53 Combination therapies that target senescent cells in the tumor microenvironment and modulate the SASP could offer new therapeutic options in cancer treatment, potentially inhibiting tumor growth while enhancing the efficacy of existing therapies like chemotherapy and immunotherapy.194,217

Preclinical Evidence Supporting Combination Therapies

In preclinical animal models, the combination of senolytic and senomorphic agents has shown promising results. For example, the combination of dasatinib and quercetin (senolytic agents) with fisetin (a senomorphic agent) has been tested in mice and humans and demonstrated enhanced effects compared to either treatment alone. In this combination, dasatinib and quercetin effectively reduced the number of senescent cells in adipose tissue and the vasculature, while fisetin modulated the inflammatory SASP, improving overall tissue function and reducing the risk of age-related diseases such as cardiovascular disease and osteoporosis.18 In another study, the combination of fisetin (a senolytic flavonoid) with sorafenib (a senomorphic agent) showed better synergistic effects in vitro and in vivo than either agent used alone against human cervical cancer.218 These findings highlight the potential of combination therapies to improve multiple aspects of aging simultaneously, rather than focusing on a single target. Table 5 highlights some preclinical animal models where the combination of senolytic and senomorphic agents have shown promising results.

Table 5.

Some Preclinical Evidence Supporting Combination Therapies of Senolytic and Senomorphic Agents

Senolytic Agent	Senomorphic Agent	Disease Model	Key Findings	Reference
Dasatinib + Quercetin	Metformin	Aging, Osteoarthritis	Reduced senescent cell burden, improved cartilage integrity in mice	[219]
Navitoclax (ABT-263)	Rapamycin	Pulmonary Fibrosis	Decreased lung fibrosis, improved respiratory function	[220]
Fisetin	Resveratrol	Cardiovascular Aging	Improved vascular function, reduced oxidative stress	[87]
Curcumin	Quercetin	Neurodegenerative Disorders	Enhanced cognitive function, reduced neuroinflammation	[153]
Piperlongumine	N-Acetylcysteine	Liver Fibrosis	Reduced hepatic senescence, improved liver function	[221,222]
UBX0101	Senomorphics (IL-1β inhibitors)	Osteoarthritis	Reduced inflammation and improved joint function	[117,223]
FOXO4-DRI	Metformin	Age-Related Sarcopenia	Increased muscle regeneration, improved mitochondrial function	[224,225]
ABT-737	Tocotrienols	Alzheimer’s Disease	Reduced amyloid plaques, improved cognitive function	[226,227]
Dasatinib + Quercetin	NAD+ Precursors (NR, NMN)	Systemic Aging	Increased lifespan, improved metabolic function	[60,228]
HSP90 Inhibitors	Resveratrol	Cancer-Associated Senescence	Reduced tumor progression, enhanced chemotherapy response	[95,229]
Fisetin	Sulforaphane	Metabolic Syndrome	Improved insulin sensitivity, reduced inflammation	[230]
BCL-XL Inhibitor (A1331852)	Rapamycin	Age-Related Cognitive Decline	Enhanced synaptic plasticity, reduced neuroinflammation	[231,232]
Quercetin	Omega-3 Fatty Acids	Cardiovascular Disease	Reduced arterial stiffness, lowered oxidative stress	[233,234]
Navitoclax	Melatonin	Hematopoietic Aging	Improved stem cell function, reduced DNA damage	[235,236]
Piperlongumine	Pterostilbene	Kidney Disease	Decreased renal fibrosis, improved kidney function	[237,238]

Clinical Validation of Senescence Biomarkers

The translation of senescence-targeted therapies into clinical practice is hindered by the lack of fully validated, standardized biomarkers for senescence burden. Commonly used markers such as p16^INK4a, SA-β-galactosidase, and SASP cytokines (eg, IL-6, IL-8) show promise in experimental models but have variable sensitivity and specificity across tissues and disease contexts.1 Their expression can be transient, context-dependent, and influenced by non-senescent cellular states, complicating interpretation in human studies. Furthermore, the invasive nature of current tissue-based assays limits their clinical utility. Advancements in liquid biopsy technologies, molecular imaging, and multi-omics profiling may enable non-invasive, longitudinal tracking of senescence burden, improving patient selection and therapeutic monitoring. However, large-scale, prospective studies are urgently needed to establish reproducibility, predictive validity, and regulatory acceptance of these biomarkers.

Clinical Trials and Translational Research

Although preclinical data are promising, the translation of combination therapies into clinical practice is still in its early stages. A few early-phase clinical trials are exploring the use of senolytics and senomorphics in combination for various aging-related conditions. For instance, a clinical trial is currently investigating the effects of dasatinib and quercetin combined with rapamycin in patients with idiopathic pulmonary fibrosis (IPF), a condition marked by senescence-driven fibrosis and inflammation.239 Preliminary results suggest that this combination can reduce fibrosis and improve lung function, demonstrating the potential of this combined approach to target both cellular senescence and its deleterious effects in humans. Similarly, clinical trials have evaluated the effects of combining NMN with other senolytic compounds in elderly populations and proved improved muscle strength, metabolism, and overall health.240,241 These studies aimed to assess whether the synergistic effects of combining senolytics and senomorphics translate into meaningful clinical outcomes, such as improved mobility, cognitive function, and quality of life. Table 6 is a tabular representation of some clinical evidence supporting combination therapies of senolytic and senomorphic agents.

Table 6.

Clinical Evidence Supporting Combination Therapies of Senolytic and Senomorphic Agents

Combination Therapy	Mechanism of Action	Target Disease/Condition	Clinical Evidence	References
Dasatinib + Quercetin	Senolytic: Induces apoptosis in senescent cells	Idiopathic Pulmonary Fibrosis (IPF)	Improved physical function and reduced senescent cell burden in patients	[242]
Navitoclax + Quercetin	Senolytic: BCL-2/BCL-xL inhibition; Quercetin as an anti-inflammatory agent	Osteoarthritis	Reduced senescent chondrocytes, improved cartilage integrity	[143]
Fisetin + Quercetin + Resveratrol	Senolytic: Removes senescent cells; Senomorphic: mTOR inhibition reduces inflammation	Age-Related Cognitive Decline	Improved cognitive function and reduced neuroinflammation	[141]
Dasatinib + Curcumin	Senolytic: Dasatinib-induced apoptosis; Senomorphic: Curcumin inhibits NF-κB	Metabolic Syndrome	Enhanced insulin sensitivity and reduced inflammatory markers	[243]
ABT-737 + Metformin	Senolytic: BCL-2 inhibitor; Senomorphic: Metformin reduces mitochondrial ROS	Type 2 Diabetes and Aging	Improved metabolic profiles and reduced inflammation	[244]
Quercetin + Resveratrol	Senolytic: Inhibits survival pathways in senescent cells; Senomorphic: SIRT1 activation	Cardiovascular Aging	Reduced arterial stiffness and improved endothelial function	[245]
Fisetin + NAC (N-Acetylcysteine)	Senolytic: Induces apoptosis; Senomorphic: Antioxidant protection	Neurodegenerative Diseases (Alzheimer’s, Parkinson’s)	Decreased neuroinflammation and improved synaptic plasticity	[240]
Dasatinib + Fisetin	Senolytic: Eliminates senescent cells; Senomorphic: Antioxidant and anti-inflammatory effects	Osteoarthritis and Frailty	Improved mobility and reduced pain in preclinical models	[246]
Hydrogen Sulfide (H2S) Donors + Metformin	Senomorphic: Enhances mitochondrial function and reduces oxidative stress	Aging-Associated Sarcopenia	Preserved muscle function and improved mitochondrial health	[247,248]
Navitoclax + Palbociclib	Senolytic: Targets BCL-2; Senomorphic: Reduces oxidative stress	Breast Cancer-Associated Senescence	Increased cancer cell apoptosis and reduced senescent tumor cells	[249]
Ginsenosides + Quercetin	Senolytic: Apoptotic induction in senescent cells; Senomorphic: NF-κB inhibition	Metabolic and Cardiovascular Aging, Anti-cancer potentials	Lowered oxidative stress and improved lipid metabolism	[250]
Bromodomain Inhibitors (JQ1) + Fisetin	Senolytic: Epigenetic modulation of senescence; Senomorphic: Antioxidant properties	Fibrosis and Chronic Lung Diseases	Reduced lung fibrosis and improved respiratory function	[251,252]
Curcumin + Senolytic Peptides	Senolytic: Selectively targets senescent cells; Senomorphic: Anti-inflammatory effects	Age-Related Macular Degeneration	Reduced retinal degeneration and improved visual function	[253]

Clinical Translation and Challenges in the Development of Senolytic and Senomorphic Therapies

The clinical translation of senolytic and senomorphic therapies is a promising but challenging endeavor. Addressing safety concerns, developing reliable biomarkers, optimizing dosing regimens, and overcoming regulatory hurdles are key to the success of these therapies in clinical settings. As ongoing clinical trials continue to yield valuable insights, the path toward effective senescence-targeting interventions for healthy aging becomes clearer. The successful development of these therapies could revolutionize aging medicine, offering novel treatments for a range of age-related diseases and enhancing the quality of life for aging populations.

Challenges in Clinical Translation

While preclinical studies have demonstrated promising results for both senolytic and senomorphic therapies, translating these findings into effective and safe clinical treatments presents several challenges. The path from bench to bedside is often complex and fraught with regulatory, safety, and efficacy concerns.

1. Safety and Toxicity: The safety of senolytic and senomorphic therapies is one of the foremost concerns in clinical translation. Although many senolytic agents, such as dasatinib and quercetin, have shown efficacy in preclinical models, their long-term effects in humans are not yet fully understood. The risk of off-target effects, immune system disruption, or toxicity when these agents are used in combination or over extended periods is still a significant challenge.254 For example, the selective removal of senescent cells by senolytics may inadvertently affect healthy cells that share certain senescent-like characteristics or may lead to inflammatory responses in tissues as a result of the clearance process.194 Additionally, long-term inhibition of pathways such as mTOR, which is involved in regulating cell growth, immune function, and metabolism, could have unintended consequences that need to be carefully studied in clinical trials.255 Thus, a key focus for the clinical development of these therapies will be determining optimal dosing regimens and ensuring the safe use of these agents without disrupting vital physiological processes.

2. Standardization of Senescence Biomarkers: A major challenge in both the development and application of senescence-targeting therapies is the identification of reliable biomarkers that can accurately assess the presence of senescent cells and their effects.256 Current biomarkers for senescence, such as p16^INK4a, β-galactosidase activity, and SASP factors, are useful in research settings, but their clinical applicability remains limited. There is a need for non-invasive, easily measurable biomarkers that can guide the use of senolytics and senomorphics, monitor treatment progress, and assess therapeutic efficacy. Furthermore, the heterogeneity of cellular senescence such as different tissues, types of senescent cells, and stages of senescence complicates the development of universal biomarkers. The presence of senescent cells in tissues may vary among individuals, with some aging populations showing greater senescence burden than others. Thus, tailored approaches for the identification and treatment of senescence in specific tissues will be necessary.257

3. Dosing and Timing: Finding the right dosing schedule for senolytics and senomorphics is critical to their success in clinical practice. The balance between efficacy and safety requires careful modulation of dosage and treatment duration. Senolytic therapies, which target and eliminate senescent cells, may need to be administered intermittently, while senomorphics, which modulate the SASP, may be more suitable for continuous or long-term treatment.36 Additionally, in combination therapies, determining the timing and synergy of different agents is complex.258 The effects of senolytic and senomorphic agents may be enhanced or diminished depending on when and how they are administered.35 Therefore, clinical trials will need to explore various combinations and schedules to identify the most effective regimen for targeting senescence and promoting healthy aging without causing harm.

Strategies for Overcoming Developmental Challenges

Strategies for overcoming developmental challenges in order to bring these promising treatments into clinical practice include:

1. Personalized Approaches: One way to address the challenges of clinical translation is through personalized medicine. Given the heterogeneity of aging and senescence across individuals, therapies may need to be tailored to specific patients based on biomarkers of senescence and their unique disease profile. Personalized approaches would allow for the more precise application of senolytic and senomorphic therapies, ensuring that individuals receive the right treatment at the right time and in the right dose.129 Advances in genomics, proteomics, and other omics technologies may facilitate the identification of biomarkers that predict senescence burden and SASP expression in different tissues. These biomarkers could guide treatment decisions, helping clinicians select the most appropriate therapies for patients based on their individual senescence profiles.259

2. Developing Novel Delivery Systems: The efficacy of both senolytic and senomorphic therapies may be influenced by how these agents are delivered to target tissues. For example, nanoparticles, liposomes, or other drug delivery systems can be engineered to deliver these agents more specifically to tissues where senescence is a major contributor to dysfunction. This could improve the therapeutic outcomes by concentrating the treatment in the affected areas and minimizing systemic side effects.260 For instance, plant-derived nanocarriers have been shown to target specific organs or tissues in preclinical models of cancer, and similar strategies could be adapted to target senescent cells in tissues affected by aging.204 Developing such targeted delivery systems could enhance the effectiveness and reduce the side effects of senescence-targeting therapies.

3. Collaboration Between Academia, Industry, and Regulatory Bodies: To accelerate the clinical translation of senolytic and senomorphic therapies, strong collaboration between academic researchers, pharmaceutical companies, and regulatory agencies is crucial. Academic research provides the foundational understanding of cellular senescence and aging, while industry partners have the resources and expertise to translate this knowledge into viable therapies.126 Regulatory bodies, such as the FDA, will play a critical role in establishing guidelines for the safe and effective use of these therapies in clinical practice. A collaborative effort can streamline the development process, reduce regulatory hurdles, and ensure that new therapies are both effective and safe.119

Future Directions in Senescence Research

As we move toward clinical application, targeting cellular senescence presents an exciting frontier in promoting healthy aging and mitigating the impact of aging-related diseases. The continuing development of senolytic and senomorphic therapies holds immense potential, but several areas require further research and refinement.

1. Expanding the Senescence Landscape: Although much progress has been made in understanding the role of senescence in aging and disease, many unanswered questions remain. Future research should aim to further elucidate the various subtypes of cellular senescence, including differences between stress-induced senescence, oncogene-induced senescence, and developmental senescence, as each may present unique therapeutic opportunities. Investigating the molecular pathways that govern these senescent states could reveal new targets for senolytic and senomorphic therapies. Moreover, expanding our understanding of senescence in different tissue types, organs, and systems will be crucial. While much of the current research focuses on senescence in skin, muscle, and adipose tissue, the role of senescence in organs like the brain, liver, and heart remains underexplored. By addressing tissue-specific senescence and its relationship with local microenvironments, we can develop therapies that more effectively target aging in diverse tissues.

2. Optimizing Combination Therapies: The synergistic use of senolytic and senomorphic agents could be an important avenue for improving therapeutic efficacy. As discussed earlier, senolytics focus on clearing senescent cells, while senomorphics aim to modify the SASP and other senescence-related pathways. Combining these therapies could enhance their individual effects, but careful optimization of dosing schedules, timing, and patient selection will be necessary. Emerging evidence suggests that a “cocktail” approach, that is, incorporating not only senolytics and senomorphics but also other therapeutic modalities, such as antioxidants, immune modulators, or metabolic enhancers may have a compounded effect in promoting healthy aging.261 Future clinical trials should explore these combination strategies, testing them in diverse age-related diseases to understand the potential for synergy and minimizing possible negative interactions between therapies.

3. Personalized and Precision Medicine: Given the heterogeneity of aging, a one-size-fits-all approach to senescence-targeting therapies is unlikely to succeed. Future studies should focus on developing personalized medicine strategies, taking into account individual variations in genetics, epigenetics, microbiome composition, and lifestyle factors. Identifying biomarkers specific to the senescence burden in each patient could allow for the development of tailored treatment plans that maximize efficacy and minimize side effects. Furthermore, the use of “big data” approaches integrating genomic, proteomic, and phenotypic information could provide valuable insights into how senescence manifests across diverse populations. This information would be essential in designing personalized interventions and refining existing therapies to be more effective and individualized.

4. Non-Invasive Monitoring Tools: The development of non-invasive technologies to monitor senescence burden and therapy efficacy will be pivotal in advancing clinical practice. Currently, many of the methods used to track cellular senescence are invasive, such as tissue biopsies or complex imaging techniques. Future research should focus on developing non-invasive biomarkers, such as blood tests or imaging technologies, that can assess senescence at the tissue level. This will enable clinicians to track treatment response in real time, adjust dosages accordingly, and determine the optimal time for intervention.

5. Expanding the Scope of Senescence-Targeting Agents: While several promising senolytic and senomorphic agents have been identified, the search for new compounds should remain a priority. Natural products, particularly phytochemicals, remain an untapped resource for developing new therapeutic agents. The pharmacological properties of compounds derived from medicinal plants and other natural sources may offer unique mechanisms for modulating senescence. Exploring these avenues could lead to the discovery of novel, safer, and more effective senescence-targeting agents. In addition, understanding how existing pharmaceuticals, such as statins, metformin, and other widely used drugs, influence cellular senescence could open new therapeutic pathways. These drugs have already been shown to impact pathways related to aging and senescence, making them candidates for repurposing in the context of age-related disorders.

Conclusion

This review accentuates that targeting cellular senescence offers a transformative strategy for promoting healthy aging and mitigating age-related pathologies. By integrating recent advances in the understanding of senescence biology with detailed analyses of senolytic and senomorphic interventions, we highlight both the therapeutic promise and translational challenges in the field. Some of the challenges include issues related to safety, optimal dosing, patient stratification, and the development of reliable biomarkers. Oxidative stress and SASP are revealed as deeply interconnected processes, emphasizing the need for dual-targeting approaches that restore redox balance while modulating the senescent cell secretome. Furthermore, bioavailability and pharmacokinetic limitations remain key barriers, warranting innovation in formulation and delivery technologies.

Future success will depend not only on refining therapeutic targets but also on optimizing dosing strategies and establishing reliable, non-invasive biomarkers for senescence, enabling safe, effective, and personalized application in clinical aging medicine. Additionally, evaluating combination strategies that harness the synergistic potential of senolytics, senomorphics, and lifestyle interventions is paramount. As we continue to refine these approaches, it is likely that senolytic and senomorphic agents will become an integral part of clinical strategies aimed at enhancing the quality of life for aging populations and mitigating the impact of age-related disorders. Ultimately, the application of senescence-targeting therapies could revolutionize the way we approach aging and aging-related diseases, offering a pathway to healthier, more productive lives as we age. The primary aim of aging and gerontology research will continue to be not just to prolong lifespan but also to improve healthspan, hence fostering a more robust and fulfilling aging experience as advancements in this field progress.

Funding Statement

No funding was received.

Abbreviations

ATM, Ataxia Telangiectasia Mutated; CDK, Cyclin-Dependent Kinase; CGAS, Cyclic GMP-AMP Synthase; DDR, DNA Damage Response; DNA, Deoxyribonucleic Acid; IL-6, Interleukin-6; NF-κB, Nuclear Factor Kappa B; ROS, Reactive Oxygen Species; SASP, Senescence-Associated Secretory Phenotype; STING, Stimulator of Interferon Genes; TGF-β, Transforming Growth Factor Beta.

Data Sharing Statement

All used data is fully presented in the manuscript.

Disclosure

The authors declare no conflicts of interest in this work.